Electrogenics Laboratories Limited (ELL) is thrilled to announce a major funding milestone, successfully raising $7.4 million to accelerate the global commercialization of its groundbreaking MOSkin dosimeter technology. Launched in 2019, ELL's innovative dosimeter offers a unique solution for accurately measuring individual radiation doses and dose rates in real-time—at precisely defined depths of skin tissue and organs. This feat positions the company at the forefront of the $35 billion radiotherapy market for cancer treatment, as well as critical imaging technologies such as angiography, CT, and X-ray scans. The funding not only highlights investor confidence in ELL's potential but also aims to propel the company toward full global distribution of the MOSkin, which has already undergone extensive testing across over 20 hospitals and clinics internationally, thanks to more than $8 million in previous grant funding.
The formidable team at ELL, led by seasoned professionals with extensive experience in advanced technology product development and international business, is poised to navigate the challenges of bringing this revolutionary product to market. Collaborations with esteemed scientific advisors from the University of Wollongong—including Distinguished Professor Anatoly Rozenfeld—alongside development partners like Genesys Electronics Design, further bolster ELL’s capabilities. With this funding, ELL seeks not only to improve patient safety and treatment outcomes but also to establish itself as the world leader in cutting-edge radiation dosimetry solutions. This funding round represents not just a financial boost, but a pivotal opportunity to save lives through innovative technology in the healthcare sector.
